Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)

A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days

(2011) Craig R. Cohen et al.   PLoS One

Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials

(2010) Bret J Rudy et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity

(2010) David Tyssen et al.   PLoS One

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

(2010) Q. Abdool Karim et al.   SCIENCE

Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A Dose Ranging, Phase I Study

(2010) John OʼLoughlin et al.   SEXUALLY TRANSMITTED DISEASES

The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies

(2009) I Mary Poynten et al.   AIDS

Microbicides for HIV prevention: reality or hope?

(2009) Ian McGowan   CURRENT OPINION IN INFECTIOUS DISEASES

A Randomized Controlled Trial of the Safety of Candidate Microbicide SPL7013 Gel When Applied to the Penis

(2009) Marcus Y Chen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES